---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-030273"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2023-06-28T23:59:59+00:00"
generated_at: "2026-06-13T15:36:41.218597+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arcus Biosciences sells 1.01M shares to Gilead at $19.26 per share under amended purchase agreement

## Summary
- Gilead to purchase 1,010,000 shares of Arcus common stock at $19.26 per share.
- Agreement amends 2021 SPA; Gilead retains option to buy up to 35% of outstanding shares until July 2025.
- Shares sold in unregistered transaction under Section 4(a)(2) to accredited investor Gilead.
- Closing subject to customary conditions.

## SEC filing metadata
- accession: 0000950170-23-030273
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2023-06-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000095017023030273/0000950170-23-030273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000095017023030273/rcus-20230627.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-030273
- JSON: https://secwatch.observer/filing/0000950170-23-030273.json
- Plain text: https://secwatch.observer/filing/0000950170-23-030273.txt

## Key facts
- Material Agreements
  Arcus Biosciences, Inc. amended Second Amended and Restated Common Stock Purchase Agreement with Gilead Sciences, Inc. (effective 2023-06-27).
  - Action: amendment
  - Agreement: equity purchase
  - Counterparty: Gilead Sciences, Inc.
  - Effective: 2023-06-27
  source text: On June 27, 2023, Arcus Biosciences, Inc. (“Arcus”) and Gilead Sciences, Inc. (“Gilead”) entered into a Second Amended and Restated Common Stock Purchase Agreement (the “A&R Purchase Agreement”), which amends and restates in its entirety the Amended & Restated Common Stock Purchase Agreement entered into between Arcus and Gilead on January 31, 2021 (the “2021 SPA”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000095017023030273/0000950170-23-030273-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.